Dr.
-Chief Technology Officer
THOMAS LEE
Dr. Thomas Lee has over 20 years of experience in pharmaceutical development with over 10 years of experience in big pharma in US. Dr. Lee joined Novartis as a Senior Scientist and subsequently was promoted to Principal Scientist and Project Leader (2003-2008). He was recruited to Celgene Corporation as a Senior Scientist (Manager) to start a new department, Formulations R&D (2008-2013). Dr. Lee served as an Assistant Professor in the School of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong from 2013 to 2018 and then joined Aptorum Therapeutics Limited as a Chief Executive Officer and Chief Scientific Officer in 2018. Later, he moved to Aptorum Group Limited to serve as the Head of Research & Development from 2019-2023. Dr. Lee contributed to the development and commercialization of four pharmaceutical products (Entresto®, Farydak®, Otezla®, Pomalyst®) and one dietary supplement (Nativuswell®) and has advanced 8 drug
candidates from discovery stage to clinical trials in US and Canada.
Dr. Lee is a registered pharmacist in Hong Kong since 1996 and was a former member of Manufacturers’ Licensing Committee, Pharmacy & Poison Board, Department of Health, Hong Kong SAR. Dr. Lee graduated with B.Pharm. (Hons) Degree from The Chinese University of Hong Kong and received his Ph.D. in Pharmaceutical Sciences (Drug Delivery) from the University of Wisconsin-Madison in US.